Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2010

Open Access 01-12-2010 | Research article

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study

Authors: Felix Bermejo-Pareja, Desiree Antequera, Teo Vargas, Jose A Molina, Eva Carro

Published in: BMC Neurology | Issue 1/2010

Login to get access

Abstract

Background

Simple, non-invasive tests for early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers for the early diagnosis of Alzheimer disease (AD) are available. The clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. A biochemical marker that would support the clinical diagnosis and distinguish AD from other causes of dementia would therefore be of great value as a screening test. A total of 126 samples were obtained from subjects with AD, and age-sex-matched controls. Additionally, 51 Parkinson's disease (PD) patients were used as an example of another neurodegenerative disorder. We analyzed saliva and plasma levels of β amyloid (Aβ) using a highly sensitive ELISA kit.

Results

We found a small but statistically significant increase in saliva Aβ42 levels in mild AD patients. In addition, there were not differences in saliva concentration of Aβ42 between patients with PD and healthy controls. Saliva Aβ40 expression was unchanged within all the studied sample. The association between saliva Aβ42 levels and AD was independent of established risk factors, including age or Apo E, but was dependent on sex and functional capacity.

Conclusions

We suggest that saliva Aβ42 levels could be considered a potential peripheral marker of AD and help discrimination from other types of neurodegenerative disorders. We propose a new and promising biomarker for early AD.
Appendix
Available only for authorised users
Literature
1.
Lansbury PT: Back to the future: the old-fashioned way to new medications for neurodegeneration. Nat Med. 2004, 10: 51-57. 10.1038/nrn1435.CrossRef
2.
Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S: Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J. 1998, 12: 17-34.PubMed
3.
Attems J, Lintner F, Jellinger KA: Olfactory involvement in aging and Alzheimer's disease: an autopsy study. J Alzheimers Dis. 2005, 7: 149-157.PubMed
4.
Frederikse PH, Garland D, Zigler JS, Piatigorsky J: Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem. 1996, 271: 10169-10174. 10.1074/jbc.271.17.10169.CrossRefPubMed
5.
Fukuchi K, Li L, Hart M, Lindsey JR: Accumulation of amyloid-beta protein in exocrine glands of transgenic mice overexpressing a carboxyl terminal portion of amyloid protein precursor. Int J Exp Pathol. 2000, 81: 231-239. 10.1046/j.1365-2613.2000.00156.x.CrossRefPubMedPubMedCentral
6.
Sousa MM, do Amaral JB, Guimarães A, Saraiva MJ: Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J. 2005, 19: 124-126.PubMed
7.
Oh YS, Turner RJ: Effect of gamma-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells. Am J Physiol Cell Physiol. 2006, 291: 76-82. 10.1152/ajpcell.00508.2005.CrossRef
8.
Scherber A, Richter K, Schaps P: Distribution of antiepileptic drugs between plasma, plasma water, cerebrospinal fluid, saliva and brain. Monogr Neural Sci. 1980, 5: 208-212.PubMed
9.
Sayer R, Law E, Connelly PJ, Breen KC: Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors. Clin Biochem. 2004, 37: 98-104. 10.1016/j.clinbiochem.2003.10.007.CrossRefPubMed
10.
Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2: 605-613. 10.1016/S1474-4422(03)00530-1.CrossRefPubMed
11.
Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007, 13: 1359-1362. 10.1038/nm1653.CrossRefPubMed
12.
German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP: Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother. 2007, 61: 383-389. 10.1016/j.biopha.2007.05.009.CrossRefPubMed
13.
American Psychiatric Association: DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington DC: American Psychiatric Association
14.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984, 34: 939-944.CrossRefPubMed
15.
Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed
16.
Calne DB, Snow BJ, Lee C: Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992, 32: 125-127. 10.1002/ana.410320721.CrossRef
17.
Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol. 1999, 56: 33-39. 10.1001/archneur.56.1.33.CrossRefPubMed
18.
Decker SA: Low salivary cortisol and elevated depressive affect among rural men in Botswana: reliability and validity of laboratory results. J Physiol Anthropol. 2006, 25: 91-101. 10.2114/jpa2.25.91.CrossRefPubMed
19.
Boston PF, Gopalkaje K, Manning L, Middleton L, Loxley M: Developing a simple laboratory test for Alzheimer's disease: measuring acetylcholinesterase in saliva - a pilot study. Int J Geriatr Psychiatry. 2008, 23: 439-440. 10.1002/gps.1882.CrossRefPubMed
20.
Aslanidis C, Schmitz G: High-speed apolipoprotein E genotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. Clin Chem. 1999, 45: 1094-1097.PubMed
21.
Yao C, Karabasil MR, Purwanti N, Li X, Akamatsu T, Kanamori N, Hosoi K: Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. J Biol Chem. 2006, 281: 7968-7976. 10.1074/jbc.M507705200.CrossRefPubMed
22.
Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT: Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003, 12: 2949-2956. 10.1093/hmg/ddg322.CrossRefPubMed
23.
Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ: A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009, 66: 190-199. 10.1001/archneurol.2008.565.CrossRefPubMedPubMedCentral
24.
25.
Blennow K: CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn. 2005, 5: 661-672. 10.1586/14737159.5.5.661.CrossRefPubMed
26.
Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006, 129: 3035-3041. 10.1093/brain/awl269.CrossRefPubMed
27.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5: 228-234. 10.1016/S1474-4422(06)70355-6.CrossRefPubMed
28.
Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H: No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2007, 130: e82-10.1093/brain/awm140.CrossRefPubMed
29.
Cook CJ: Rapid noninvasive measurement of hormones in transdermal exudate and saliva. Physiol Behav. 2002, 75: 169-181. 10.1016/S0031-9384(01)00658-8.CrossRefPubMed
30.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994.CrossRefPubMed
31.
Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003, 289: 2094-2103. 10.1001/jama.289.16.2094.CrossRefPubMed
32.
Dietrich MO, Spuch C, Antequera D, Rodal I, de Yébenes JG, Molina JA, Bermejo F, Carro E: Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging. 2008, 29: 902-912. 10.1016/j.neurobiolaging.2007.01.008.CrossRefPubMed
33.
Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Bush AI: Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet. 2003, 361: 1258-1265. 10.1016/S0140-6736(03)12981-9.CrossRefPubMed
34.
Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM: Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000, 57: 100-105. 10.1001/archneur.57.1.100.CrossRefPubMed
35.
Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995, 38: 643-648. 10.1002/ana.410380413.CrossRefPubMed
36.
Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, Hirai S, Furiya Y, Endoh R, Mori H: Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997, 148: 41-45. 10.1016/S0022-510X(96)00314-0.CrossRefPubMed
37.
Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998, 55: 937-945. 10.1001/archneur.55.7.937.CrossRefPubMed
38.
Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL: CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology. 1999, 52: 547-551.CrossRefPubMed
39.
Ship JA, DeCarli C, Friedland RP, Baum BJ: Diminished submandibular salivary flow in dementia of the Alzheimer type. J Gerontol. 1990, 45: 61-66.CrossRef
40.
Chodobski A, Szmydynger-Chodobska J: Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech. 2001, 52: 65-82. 10.1002/1097-0029(20010101)52:1<65::AID-JEMT9>3.0.CO;2-4.CrossRefPubMed
41.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002, 8: 1390-1397. 10.1038/nm793.CrossRefPubMed
42.
Ray I, Chauhan A, Wegiel J, Chauhan VP: Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res. 2000, 853: 344-351. 10.1016/S0006-8993(99)02315-X.CrossRefPubMed
43.
Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL: Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature. 1986, 323: 455-458. 10.1038/323455a0.CrossRefPubMed
44.
Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I: Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis. 2008, 14: 17-25.PubMed
45.
Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, Ferrer I, Bermejo-Pareja F, Carro E: Cytoplasmic gelsolin increases mitochondrial activity and reduces Aβ burden in a mouse model of Alzheimer's disease. Neurobiol Dis. 2009, 36: 42-50. 10.1016/j.nbd.2009.06.018.CrossRefPubMed
46.
Southwick PC, Yamagata SK, Echols CL, Higson GJ, Neynaber SA, Parson RE, Munroe WA: Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996, 66: 259-265. 10.1046/j.1471-4159.1996.66010259.x.CrossRefPubMed
Metadata
Title
Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study
Authors
Felix Bermejo-Pareja
Desiree Antequera
Teo Vargas
Jose A Molina
Eva Carro
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2010
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-10-108

Other articles of this Issue 1/2010

BMC Neurology 1/2010 Go to the issue

Research article

Percutaneous radiofrequency lesions adjacent to the dorsal root ganglion alleviate spasticity and pain in children with cerebral palsy: pilot study in 17 patients

Research article

Conduction in ulnar nerve bundles that innervate the proximal and distal muscles: a clinical trial

Research article

Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships

Research article

Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study

Research article

Evidence based guidelines for complex regional pain syndrome type 1

Case report

A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine/valine at codon 129: Case report